Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer

  • Technology appraisal guidance
  • TA424
  • Published: 

Review decision – October 2020

Decision that the existing guidance remains unchanged

We would like to update you on the decision made regarding the review of the existing guidance on TA424; Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer.

Stakeholders were asked to inform NICE as to whether they believed that the guidance remains relevant or whether there is an evidence based case for updating the existing recommendations.

Based on the information received, NICE does not believe that an update of the guidance is required at this time. The guidance will therefore remain unchanged, in its current form, unless or until NICE becomes aware of substantive information which would make it reconsider.

Review decision paper

This page was last updated: